NCT00626015View on ClinicalTrials.gov

Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Malignant Neoplasms of Brain
Interventions
BIOLOGICAL

PEP-3-KLH conjugate vaccine

Given intradermally

BIOLOGICAL

daclizumab

Given IV

DRUG

temozolomide

Given by mouth.

OTHER

placebo

Given IV

BIOLOGICAL

PEP-3-KLH

Basiliximab 20 mg IV over 30 minutes with PEP-3-KLH vaccine # 1 only.

Trial Locations (1)

27710

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

John Sampson

OTHER

NCT00626015 - Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery | Biotech Hunter | Biotech Hunter